Automate Your Wheel Strategy on EXEL
With Tiblio's Option Bot, you can configure your own wheel strategy including EXEL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EXEL
- Rev/Share 8.5247
- Book/Share 8.0497
- PB 5.2909
- Debt/Equity 0.0817
- CurrentRatio 3.7516
- ROIC 0.2536
- MktCap 11418896767.0
- FreeCF/Share 2.8057
- PFCF 15.1624
- PE 16.8638
- Debt/Assets 0.0625
- DivYield 0
- ROE 0.3164
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | EXEL | Morgan Stanley | Overweight | Equal Weight | -- | $48 | Jan. 8, 2026 |
| Downgrade | EXEL | BofA Securities | Neutral | Underperform | -- | $41 | Jan. 5, 2026 |
| Initiation | EXEL | Wolfe Research | -- | Peer Perform | -- | -- | Nov. 18, 2025 |
| Downgrade | EXEL | Guggenheim | Buy | Neutral | -- | -- | Nov. 3, 2025 |
| Upgrade | EXEL | Leerink Partners | Market Perform | Outperform | -- | $48 | Oct. 21, 2025 |
| Resumed | EXEL | Barclays | -- | Equal Weight | -- | $40 | Sept. 19, 2025 |
| Resumed | EXEL | Barclays | -- | Equal Weight | -- | $40 | Sept. 17, 2025 |
| Initiation | EXEL | Goldman | -- | Buy | -- | $47 | Sept. 17, 2025 |
| Downgrade | EXEL | RBC Capital Mkts | Outperform | Sector Perform | $45 | $50 | July 8, 2025 |
| Upgrade | EXEL | Stephens | Equal Weight | Overweight | -- | $60 | June 24, 2025 |
News
Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy?
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Should Value Investors Buy Exelixis (EXEL) Stock?
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
EXEL vs. EXAS: Which Stock Is the Better Value Option?
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or Exact Sciences (EXAS). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
Published: January 15, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
Published: January 14, 2026 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Exelixis Posts Preliminary '25 Results, Issues '26 Outlook
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Neutral
EXEL posts approximately $2.32B in 2025 revenues and guides $2.525 -$2.625B for 2026 as Cabometyx grows and a zanzalintinib NDA advances.
Read More
Here's Why Exelixis (EXEL) is a Strong Value Stock
Published: January 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study
Published: January 08, 2026 by: Zacks Investment Research
Sentiment: Positive
Exelixis teamed with Natera on the phase III STELLAR-316 study testing zanzalintinib in resected stage II/III colorectal cancer. Stock gains.
Read More
See How Rare Bullish Inflows Lift Outliers Like Exelixis
Published: December 31, 2025 by: FXEmpire
Sentiment: Positive
Exelixis, Inc. (EXEL), an oncology-focused biopharmaceutical firm, is up 81% since a Big Money boost starting in 2021.
Read More
Here's Why Exelixis (EXEL) is a Strong Growth Stock
Published: December 31, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
Published: December 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Why Is Exelixis (EXEL) Up 9% Since Last Earnings Report?
Published: December 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
Read More
Here's Why Exelixis (EXEL) is a Strong Growth Stock
Published: November 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Why Exelixis (EXEL) International Revenue Trends Deserve Your Attention
Published: November 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Evaluate Exelixis' (EXEL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Read More
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Published: November 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
Published: November 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Exelixis, Inc. (EXEL) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
Published: November 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Exelixis, Inc. ( EXEL ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 10, 2025 10:30 AM EST Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants Michael Schmidt - Guggenheim Securities, LLC, Research Division Presentation Michael Schmidt Guggenheim Securities, LLC, Research Division Welcome to this next fireside chat with Exelixis. With us today, we have Mike Morrissey, President and CEO.
Read More
EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis posts strong Q3 results with earnings and revenue beats, boosted by Cabometyx sales, and narrows 2025 guidance.
Read More
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Here's Why Exelixis (EXEL) is a Strong Value Stock
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Exelixis, Inc. (EXEL) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
Published: September 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Exelixis, Inc. (NASDAQ:EXEL ) Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 8:50 AM EDT Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants Courtney Breen - Sanford C. Bernstein & Co., LLC.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
Published: September 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Exelixis, Inc. (EXEL) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Exelixis, Inc. (NASDAQ:EXEL ) H.C. Wainwright 27th Annual Global Investment Conference September 10, 2025 8:00 AM EDT Company Participants Christopher Senner - Executive VP & CFO Andrew Peters - Senior Vice President of Strategy Conference Call Participants Robert Burns - H.C.
Read More
About Exelixis, Inc. (EXEL)
- IPO Date 2000-04-17
- Website https://www.exelixis.com
- Industry Biotechnology
- CEO Michael Morrissey
- Employees 1147